GSK : Summary for GlaxoSmithKline PLC - Yahoo Finance

U.S. Markets close in 6 hrs 24 mins

GlaxoSmithKline plc (GSK)


NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
42.34+0.06 (+0.14%)
As of 9:36AM EDT. Market open.
People also watch
AZNNVSSNYLLYBMY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close42.28
Open42.22
Bid0.00 x
Ask0.00 x
Day's Range42.19 - 42.35
52 Week Range37.20 - 45.58
Volume152,216
Avg. Volume3,322,925
Market Cap102.11B
Beta1.04
PE Ratio (TTM)93.26
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield2.00 (4.74%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters2 hours ago

    Crunch week looms for Sanofi, Roche and GSK at U.S. drugs agency

    Three of Europe's top drugmakers face critical verdicts from U.S. regulators next week, with Sanofi and Roche likely to win approvals for two new products, while GlaxoSmithKline braces for a potential generic rival. Given earlier impressive clinical trial results, investors expect the Food and Drug Administration (FDA) to clear both Roche's multiple sclerosis (MS) treatment Ocrevus and Sanofi's new eczema drug Dupixent.

  • The Wall Street Journal9 hours ago

    [$$] AT&T, Verizon Pull Ads From Google Over ‘Hate’ Videos

    AT&T and Verizon Communications pulled much of their advertising from Google over concerns that their ads may have run alongside controversial videos, extending the financial impact of a controversy.

  • Reuters14 hours ago

    GSK and Regeneron to mine gene data from 500,000 Britons

    Britain's GlaxoSmithKline and U.S.-based Regeneron Pharmaceuticals are embarking on a joint project with UK Biobank, the world's most detailed biomedical database, to hunt for new clues linking genes and disease. By analysing genetic variations and health in 500,000 middle-aged and older Britons, the partners said on Thursday they hoped to identify promising leads for new medicines. The aim is to analyse DNA from an initial 50,000 samples by the end of 2017, using Regeneron's large gene sequencing centre in New York.